Seres Therapeutics, Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|
| Revenue | $28.3M | $32.1M | $21.8M | $0 | — | — |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $96.0M | $89.5M | $82.0M | $38.1M | $10.7M | $4.8M |
| SG&A Expense | $32.6M | $34.0M | $32.6M | $16.8M | $4.4M | $1.2M |
| Operating Income | $-100.3M | $-91.4M | $-92.8M | $-54.9M | $-15.1M | $-6.1M |
| Operating Margin | -354.8% | -284.7% | -426.5% | — | — | — |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-98.9M | $-89.4M | $-91.6M | $-54.8M | $-16.7M | $-6.1M |
| Net Margin | -350.0% | -278.4% | -420.7% | — | — | — |
| EPS (Basic) | $-2.43 | $-2.21 | $-2.30 | $-2.33 | $-2.67 | $-1.09 |
| EPS (Diluted) | $-2.43 | $-2.21 | $-2.30 | $-2.33 | $-2.67 | $-1.09 |
| Shares Outstanding (Basic) | 40.9M | 40.6M | 40.4M | 39.1M | 6.9M | — |
| Shares Outstanding (Diluted) | 40.9M | 40.6M | 40.4M | 39.1M | 6.9M | — |
| Dividends Per Share | — | — | — | — | — | — |